Last update Aug. 21, 2014
Inhibitor of Epidermal Growth Factor receptor that acts by inhibition of tyrosine kinase phosphorylation and used for treatment of several types of cancer.
At latest update, relevant published data on excretion into breast milk were not found.
Because of high serum protein-binding capacity, excretion into breast milk in significant amount is seemingly unlikely.
If continuation of safely breastfeeding is desired without assuming high risk for potentially severe side-effects, elimination of total burden of drug should be kept. For this to happen, breastfeeding should be stopped for 10 half-lives (T ½).
It means wait 15 days after the last dose before resuming breastfeeding.
Meanwhile, frequent pump-and-dump is recommended for maintenance of milk production.
We do not have alternatives for エルロチニブ塩酸塩.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM